Outlook Therapeutics (FRA:41O) Total Liabilities : €177.80 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Outlook Therapeutics Total Liabilities?

Outlook Therapeutics's Total Liabilities for the quarter that ended in Mar. 2024 was €177.80 Mil.

Outlook Therapeutics's quarterly Total Liabilities declined from Sep. 2023 (€43.79 Mil) to Dec. 2023 (€42.21 Mil) but then increased from Dec. 2023 (€42.21 Mil) to Mar. 2024 (€177.80 Mil).

Outlook Therapeutics's annual Total Liabilities increased from Sep. 2021 (€15.47 Mil) to Sep. 2022 (€19.99 Mil) and increased from Sep. 2022 (€19.99 Mil) to Sep. 2023 (€43.79 Mil).

Outlook Therapeutics Total Liabilities Historical Data

The historical data trend for Outlook Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Outlook Therapeutics Total Liabilities Chart

Outlook Therapeutics Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Total Liabilities

Get a 7-Day Free Trial

25.34

14.35

15.47

19.99

43.79

Outlook Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															40.66	46.10	43.79	42.21	177.80

Outlook Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Outlook Therapeutics's Total Liabilities for the fiscal year that ended in Sep. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	43.788	+	(0	+	0.0060000000000002
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	43.79

Total Liabilities	=	Total Assets (A: Sep. 2023 )	-	Total Equity (A: Sep. 2023 )
	=	30.266	-	-13.528
	=	43.79

Outlook Therapeutics's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	49.754	+	(0	+	128.05
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	177.80

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	54.307	-	-123.497
	=	177.80

Outlook Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Outlook Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Outlook Therapeutics (FRA:41O) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Outlook Therapeutics Inc (FRA:41O) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

OTLK:USA 41ON:Germany

Address

485 Route 1 South Building F, Suite 320, Iselin, NJ, USA, 08852

Website

https://www.outlooktherapeutics.com

Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications.

Outlook Therapeutics (FRA:41O) Headlines

No Headlines